By Fraiser Kansteiner
Just days before Pfizer and Medivation unveiled their merger plans in August 2016, Medivation's then-business development lead bought stock options in Incyte Corporation, the SEC says. After news of Pfizer's Medivation buyout broke, Incyte's shares jumped.
read more
By Dave Muoio
Beyond playing whack-a-mole with individual pieces of content, social media platforms need to take a proactive approach to developing and surfacing trustworthy information, representatives said during a HIMSS21 virtual panel.
read more
By Nick Paul Taylor
Neuroscience has zoomed up the agenda at Eli Lilly as the combination of data on donanemab and the accelerated approval of Biogen’s Aduhelm has opened up an opportunity in Alzheimer’s disease. Lilly has responded by splitting off its late-phase neurodegeneration and pain prospects into a new business unit.
read more
By Heather Landi
Memorial Health System in Ohio is struggling to restore its IT systems after a cyberattack Sunday that has significantly disrupted care and forced medical personnel to use paper records.
read more
By Noah Higgins-Dunn
Roche's Genentech warned that the "unprecedented" surge in demand for its arthritis drug Actemra, used to treat severely ill COVID-19 patients, has driven a global shortage that could last for months if the pandemic continues at its current pace.
read more
By Dave Muoio
The deal marries "the nation's largest" data set on consumers' health behaviors with Unite Us' social needs screening and referral platform.
read more
By Andrea Park
After nearly two decades developing excimer lasers to treat both dermatological conditions and peripheral artery disease, Ra Medical is now pursuing a “divide and conquer” strategy with the sale of its skin care business.
read more
By Angus Liu
Unlike other high-tech stocks such as Amazon and Apple where Warren Buffett is playing the long game, the Oracle of Omaha was apparently in Biogen for the short run.
read more
By Kyle LaHucik
NuChem Sciences and OmegaChem are merging to create what they consider to be Canada's largest contract research organization in chemical drug discovery. The Québécois companies will combine forces with $37 million in funding from investors.
read more
By Kyle LaHucik
With lupus nephritis med Lupkynis under its belt, Canadian biopharma Aurinia Pharmaceuticals is shelling out $7 million for two new preclinical assets to build out the next phase of its pipeline. The company has acquired Thunderbolt Pharma and inked a global licensing and research agreement with Riptide Bioscience to grow beyond Lupkynis, according to a Tuesday statement.
read more
By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner
Qualigen is calling it quits on its COVID-19 antiviral program after the FDA asked for more clinical studies before human testing. Twitter is ratcheting up its fight against vaccine misinformation after the White House blamed social media for "killing people." Plus more headlines.
read more
.png)
